Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy

CYP2C19 is one of the principal enzymes involved in the bioactivation of the antiplatelet prodrug clopidogrel. A common loss-of-function allele, CYP2C19*2 (c.681G>A; rs4244285), is associated with increased risk for serious adverse cardiovascular events in both heterozygous and homozygous patient...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Scott, SA, Sangkuhl, K, Gardner, EE, Stein, CM, Hulot, J-S, Johnson, JA, Roden, DM, Klein, TE, Shuldiner, AR
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2011
Matèries:
Translation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3234301/
https://ncbi.nlm.nih.gov/pubmed/21716271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/clpt.2011.132
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars